Oesophageal cancer metastases: An observational study of a more aggressive approach

Table 2 Treatment of synchronous and metachronous oligometastatic oesophageal carcinoma

Patient	Synchronous metastases	Type	Treatment	Metachronous metastases	Type	Time to recurrence in mo	Treatment	Survival post recurrence in mo	Alive at study endpoint	Overall survival in mo
1	Yes	Locally advanced1	Walsh regimen	Yes	Lung	11.5	Stereotactic radiotherapy	36.4	No	47.9
2	Yes	Coeliac axis	Walsh regimen + CROSS + radial gastrectomy	Yes	Left para-aortic nodes	17.9	Chemotherapy (Epirubicin, Oxaliplatin + Capecitabine)	65.4	Yes	83.3
3	Yes	Liver	Carbo5FU; 60 Gy + oesophagectomy	No	NA	NA	NA	NA	No	23.6
4	Yes	Locally advanced2	Walsh regimen + oesophagectomy	No	NA	NA	NA	NA	Yes	102.8
5	No	NA	NA	Yes	Lung	32.9	Left upper lobectomy (VATS)	97.4	No	130.3
6	No	NA	NA	Yes	Lung	16.7	Chemotherapy (carbo/taxol + FOLFOX)	21.9	No	38.6
7	No	NA	NA	Yes	Lung	19.2	Wedge resection (VATS)	26.1	No	45.3
8	No	NA	NA	Yes	Adrenal	29.7	Adrenalectomy	62.1	Yes	91.8
9	No	NA	NA	Yes	Adrenal	15.9	Adrenalectomy + chemotherapy (irinotecan)	118.9	Yes	134.8
10	No	NA	NA	Yes	Liver	33.0	Resection + chemotherapy	51.9	Yes	84.9
11	No	NA	NA	Yes	Paraaortic + Retroperitoneal	15.7	Chemotherapy (FOLFOX)	14.9	Yes	30.6

¹Right innominate artery and pars membrane of the trachea with a right 1 cm subcarinal adenopathy and left 5 mm paratracheal node on staging whole-body positron emission tomography-computed tomography (squamous cell carcinoma, T4N1M1).

²1 cm fluorodeoxyglucose avid right supraclavicular node on staging positron emission tomography-computed tomography.

NA: Not applicable; VATS: Video-assisted thoracoscopic surgery; FOLFOX: Folinic acid, fluorouracil, oxaliplatin; CROSS: The Dutch Chemoradiotherapy for Oesophageal Cancer Followed by Surgery study–weekly carboplatin and paclitaxel with concurrent radiotherapy; Carbo5FU: Carboplatin/5-fluorouracil.